Thoracoscopic lobectomy, also referred to as video-assisted thoracoscopic surgery (VATS) lobectomy, is associated with many outcome advantages compared with lobectomy by thoracotomy. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Recently, it has been proposed that surgical outcomes are superior with thoracoscopic lobectomy, based on analysis of postoperative complications in single institutional series. [12] [13] [14] However, to date there is no large randomized trial comparing VATS lobectomy to lobectomy by thoracotomy.
In the absence of robust data from phase III trials, we queried the Society of Thoracic Surgeons (STS) General Thoracic Database (STS-GTD) to compare the postoperative mortality and morbidity following open and thoracoscopic lobectomy. A propensity-matched analysis using a large national database may enable a more powerful and comprehensive comparison of postoperative outcomes.
PATIENTS AND METHODS Data Source
The STS has maintained a prospective database of patients having cardiothoracic surgery in the United States since 1987 with the database expanded in 1999 to include general thoracic surgery operations. At the time of the latest report, there were more than 80 participating sites (hospitals, group practices, or individual surgeons). Harvested data are maintained and analyzed by the Duke Clinical Research Institute in compliance with the Health Insurance Portability and Accountability Act of 1996. Variables are collected on a standardized data form that includes information about patient demographics, medical history, surgical procedures, cancer staging, and outcome (http://www.ctsnet.org/file/ ThoracicDCFV2_07_Nonannotated.pdf). Institutional Review Boards of each participating site approved the use of this database for quality improvement research. The collection and maintenance of the general thoracic surgery portion of the database has been described elsewhere. 15, 16 
Patient Population
The study population consists of patients having lobectomy as the primary procedure at STS-participating hospitals between January 1, 2002, and December 31, 2007 . All data were collected using STS-GTSD 1.30, 1.31, 2.06, 2.061, and 2.07 data collection forms. Patients were excluded from the study if they had prior thoracic surgery, a pulmonary procedure other than lobectomy, an approach other than thoracoscopy and thoracotomy was listed, if both thoracoscopy and thoracotomy were listed as the approach, and if data were missing on age (6 patients, 0.13% excluded from analysis) and gender (17 patients, 0.27% excluded from analysis). Six thousand three hundred twenty-three patients were identified (5042 having thoracotomy, 1281 having thoracoscopy; Appendix Table 1 ). The distribution of techniques used for lobectomies performed during that time interval is shown in Figure 1 .
Data Collection and Statistical Model
Data collected for each patient included continuous variables [age at time of surgery, body mass index with missing values (9.2% missing) entered according to gender-specific median values, forced vital capacity as a percent of predicted with missing values (27. 11% missing) entered according to median values, forced expiratory volume in 1 second as a percent of predicted with missing values (22.81% missing) entered according to median values, carbon monoxide diffusing capacity as a percent of predicted with missing values (42.15% missing) entered according to median values]; binary variables (0% missing) with all missing values defaulted to ''no'' per the STS database [hypertension, preoperative thoracic radiation therapy, congestive heart failure, coronary artery disease, peripheral vascular disease, preoperative steroid use steroid, current smoker (patient smokes or quit less than 1 month), cerebrovascular disease, diabetes, and renal insufficiency (dialysis or creatinine level greater than 2)]; and categorical variables [Zubrod score (5.05% missing), American Society of Anesthesiologists Risk Scale (7.92% missing), status (clinical status of the patient at the time of the primary surgical procedure; 3.67% missing), and clinical (43% missing) and pathologic cancer stage (23% missing)]. Clinical stage was not included in the model due to the significant amount of missing data. Missing data variables were treated as above to limit the introduction of bias by their exclusion.
Propensity scores were estimated using a logistic model including the following variables: age, gender, Zubrod score, American Society of Anesthesiologists Risk Scale, body mass index, hypertension, coronary artery disease, congestive heart failure, renal insufficiency, diabetes, current smoker, preoperative chemotherapy or radiotherapy, cerebrovascular disease, steroid use, clinical status, forced vital capacity as a percent of predicted, forced expiratory volume in 1 second as a percent of predicted, and carbon monoxide diffusing capacity as a percent of predicted. Patients were then matched using a Greedy 5 to 1 digit matching algorithm. 17 Missing values in Zubrod score, American Society of Anesthesiologists Risk Scale, and clinical status were kept as separate levels. Standardized difference [(X 2 À X 1 )/((S 2 2 þ S 1 2 )/2) 1/2 , where X 1 and X 2 are samples means in the thoracotomy and groups, respectively, and S 2 2 þS 1 2 are the sample standard deviations] was used to assess significance in differences of preoperative variables as well as clinical and pathologic staging between the 2 groups (>20 and<À20 being significantly different). Standardize difference was used rather than P value as it has been shown by others to not be sensitive to sample size, as P value is, and hence better for propensity matching. 18 Matching based on propensity scores produced 1281 patients in each group for analysis of postoperative outcomes (Table 1) . Postoperative outcomes analyzed for each group were assessed for significance (P values) based on McNemar tests (matched comparison) or Pearson chi-square (unmatched comparison) for categorical outcomes and Wilcoxon signed-rank tests for continuous outcomes with significance adjusted for Bonferroni correction where needed ( Table  2) . Postoperative outcomes as well as clinical and pathologic staging of the unmatched cohort of 6323 patients can be found in the appendix for comparison (Appendix Tables 2-5 ). Analysis was performed using S-Plus 6 (Insightful Corp, Seattle, WA) and SAS 9.1 (SAS Institute, Cary, NC).
RESULTS

Patient Characteristics
The baseline characteristics of the 1281 patients in each group who were derived by propensity matching from the initial cohort of 6323 patients are shown in Table 1 . A total of 83 centers participating in the STS-GTD contributed patients to these matched groups (70 having VATS, 83 having thoracotomy). The contribution from each center can be found in Appendix Table 2 . As designed, the baseline characteristics of the 2 cohorts are statistically similar for the preoperative variables used for propensity matching.
The clinical and pathologic stages for the matched cohorts are shown in Table 2 . Clinical staging information was missing in a large number of patients in both groups including 430 patients (33.6%) who had VATS lobectomy and 591 patients (46.1%) who had an open lobectomy. There was no statistically significant difference in the pathologic stage distribution between the 2 groups, with the majority of lobectomies performed for pathologic stage I disease. Thus, although clinical and pathologic stages were not included in the propensity matching analysis, the final pathologic stage distribution in the 2 groups is similar.
Perioperative Mortality and Morbidity
Analysis of the propensity-matched groups for postoperative outcomes demonstrated that VATS lobectomy was associated with significantly lower morbidity: 945 patients 
Abbreviations and Acronyms
STS ¼ Society of Thoracic Surgeons STS-GTD ¼ Society of Thoracic Surgeons General Thoracic Database VATS ¼ video-assisted thoracoscopic surgery (73.8%) of patients who had thoracoscopic lobectomy had no complications, compared with 837 patients (65.3%) of those who had lobectomy by thoracotomy (P < .0001). There was no difference in operative mortality (Table 3) . Specific postoperative complications included in the STS-GTSD are also compared in the 2 matched groups ( Table 3) . Compared with lobectomy via thoracotomy, VATS lobectomy was associated with a lower incidence of overall ASA, American Society of Anesthesiologists Risk Scale; BMI, body mass index; DLCO predicted, carbon monoxide diffusing capacity as a percent of predicted; FEV predicted, forced expiratory volume in 1 second as a percent of predicted; FVC predicted, forced vital capacity as a percent of predicted; SD, standard deviation.
)/2) 1/2 , X 1 and X 2 are samples means in the thoracotomy and thoracoscopy groups respectively, and S 2 2 þ S 1 2 are the sample standard deviations. Differences less thanÀ20 and greater than 20 are significant (at least P < .05).
pulmonary complications (7.6% vs 12.2%; P ¼ .0001). Specific subgroup analysis showed that patients who had VATS lobectomy had significantly fewer reintubations postoperatively compared with those who had lobectomy via thoracotomy. Similarly, overall cardiovascular morbidity was significantly lower in the VATS lobectomy group (8.3% vs 13.0%, P ¼ .0002), with a significant reduction noted in atrial arrhythmias requiring treatment [93 patients (7.3%) vs 147 patients (11.5%), P ¼ 0.0004]. There was no difference detected among other cardiovascular complications.
The frequency of blood transfusions was also significantly lower following VATS lobectomy (2.4% vs 4.7%, P ¼ .0028). Although the frequency of overall infectious complications was lower after lobectomy, the difference did not achieve statistical significance after Bonferroni adjustment for multiple comparisons.
Operative Time, Chest Tube Duration, and Length of Stay
Operative time, measured from the time of skin incision, was higher for VATS lobectomy, with a median increase in operative time of 30 minutes (median 173 vs 143 minutes, P <.0001). Although the frequency of prolonged air leaks (>5 days) were similar for both cohorts (7.57% vs 8.67%, P ¼ .3531), VATS lobectomy was associated with earlier chest tube removal (median 3 days vs 4 days, P < .0001; Table  4 ). Length of stay was also shorter by a median of 2 days for those having VATS lobectomy (median 4 days vs 6 days, P < .0001).
DISCUSSION
In this study, analyzing the incidence of postoperative complications using a propensity-matched analysis of patients in the STS-GTD, VATS lobectomy is associated with lower postoperative morbidity compared with thoracotomy, with a lower overall complication rate and lower rates of several individual complications, including atrial fibrillation. Although the results of this study do not rise to the level 1 evidence obtained from randomized trials, the propensity-matching analysis used in the current analysis reduces many of the biases inherent in retrospective single-institution case series.
This study suggests that VATS lobectomy should be performed in appropriately selected patients with lung cancer. Notwithstanding a phase II trial conducted by the Cancer and Leukemia Group B (CALGB 39802) demonstrating the safety and feasibility of lobectomy, 19 the acceptance of VATS lobectomy into the national general thoracic practice remains limited. In 2007, nearly 70% of all lobectomies reported to the STS-GTD were still performed via open thoracotomy (Figure 1 ). 15 The lack of wider national and international application of VATS lobectomy may be due to the relatively steep learning curve required for the procedure, the fact that most practicing surgeons did not learn the procedure in training (including general surgeons who still perform lobectomy), 20 and concerns regarding oncologic efficacy. However, experience with this procedure has demonstrated that it can be taught and practiced safely 2,3,21 and that the operation is at least as oncologically effective. 2, 3, 22 The concept that thoracoscopic lobectomy may have a lower complication profile has recently been analyzed in single-institution series including patients having VATS lobectomy and patients having open lobectomy. In 1 study, 122 patients having VATS lobectomy and 122 patients having lobectomy by thoracotomy were compared. 12 Overall, the incidence of postoperative complications was lower in the VATS group (17.2% vs 27.9%, P ¼ .046); however, these patients were matched for age and sex only, and there was no significant difference in the incidence of any of the specific complications reported. In another study, limited to the analysis of elderly patients, VATS lobectomy resulted in a significantly lower rate of complications compared with thoracotomy (28% vs 45%, P ¼ 0.04). 13 However, this series was limited to patients with clinical stage I nonsmall-cell lung cancer, and the incidence of several specific complications analyzed individually was not significantly different between the 2 groups. A propensity analysis of a larger group of patients from these series demonstrated a numerical, but not statistically significant, improvement in survival. 23 In a larger study comparing outcomes of VATS lobectomy compared with thoracotomy, a propensity-matched analysis based on preoperative variables and stage as performed, comparing 284 patients in each group. 14 In this study, 69% of those who had VATS lobectomy had no complications, versus 51% who had thoracotomy (P ¼ .0001).
In addition, VATS lobectomy was associated with a lower incidence of atrial fibrillation (13% vs 21%; P ¼ .01), less atelectasis (5% vs 12%; P ¼ .006), fewer prolonged air leaks (13% vs 19%; P ¼ .05), fewer transfusions (4% vs 13%; P ¼ .002), less pneumonia (5% vs 10%; P ¼ .05), less renal failure (1.4% vs 5%; P ¼ .02), shorter chest tube duration (median 3 vs 4 days; P < .0001), and shorter length of hospital stay (median 4 vs 5 days; P < .0001). 14 In this study, VATS lobectomy was associated with fewer overall complications, as well as with specific complications that are recognized to have an important impact on cost and outcome. The frequency of postoperative atrial arrhythmias has now been demonstrated to be significantly lower after thoracoscopic lobectomy. Atrial fibrillation is a significant source of morbidity after cardiothoracic surgery and often prolongs hospital stay by requiring the need for extended telemetry monitoring, anticoagulation, or pharmacologic cardioversion. 24, 25 The lower incidence of atrial arrhythmias after VATS lobectomy may be due to decreased levels of cytokines and other inflammatory immunodulators released after thoracoscopic techniques compared with thoracotomy. 26 The results of the current analysis also demonstrate that the incidence of postoperative pulmonary complications were significantly lower after VATS lobectomy (7.6% vs 12.2%). In particular, the need for reintubation was less frequent after lobectomy compared with lobectomy by thoracotomy, but the incidence of other complications was not statistically different in the 2 groups. Although the reason for this reduction is unclear, it may be due to optimal postoperative pain control in the VATS lobectomy group, which has been demonstrated in numerous studies. 4, 5, 8, 9 As the use of epidural anesthesia and postoperative pain scores were not recorded in the STS-GTD, this cannot be confirmed by this study. In addition, thoracoscopic lobectomy is associated with a lower transfusion rate, a lower postoperative infection rate, shorter chest tube duration, and shorter length of stay, compared with thoracotomy by lobectomy.
The impact of VATS lobectomy on postoperative morbidity in our cohort of 2562 patients may have been underestimated by the relatively young age and the lack of major cardiopulmonary comorbidity in patients in both cohorts. The majority of patients were free of coronary artery disease (>85%), congestive heart failure (>95%), and renal insufficiency (>98%), and both groups had relatively well-preserved pulmonary function. A recent analysis of the Surveillance, Epidemiology, and End-Results (SEER)-Medicare database from 1992 to 2002, showed that patients with resectable lung cancer are now older (median age: 67 years) and more frequently present with significant comorbidities. 26, 27 Given these trends, VATS lobectomy may be of even greater benefit in a population that is typically older and with more comorbidities than our study population. 4, 28 The demonstration of reduced complications after VATS lobectomy should have important ramifications in the care of patients after lobectomy. VATS lobectomy is associated with a lower overall incidence of complications, as well as a reduction of several specific complications, suggesting that VATS lobectomy may actually be a safer operation in appropriately selected patients. In addition, the minimally invasive approach should offer important economic advantages, as the management of postoperative complications will significantly increase the cost of surgical management. Furthermore, considering that VATS lobectomy is also associated with a shorter length of stay, the apparent comparative effectiveness of VATS lobectomy is further magnified.
We recognize that there are important limitations to this analysis. Although propensity matching reduces the bias inherent in a comparison of 2 surgical techniques, it is not equivalent to a prospective, randomized trial. In this voluntary data set, over 10% of patients had missing entry of preoperative variables, including demographics, pulmonary function tests, and clinical stage. In general, patients with missing data were not excluded from analysis to prevent the introduction of an unknown confounder. Clinical stage was not used in the matching process as a significant portion of these data were also missing in both groups, as shown in Table 2 . Although there was a statistically higher portion of clinical stage I patients in the VATS group, the proportion of clinical stage I and II patients were statistically similar between the 2 groups, which is the cohort of patients in which VATS lobectomy are typically performed. Although not used in the matching algorithm, there was no difference in overall pathologic stage distribution between the 2 groups. Of note, 2 separate propensity scoring models incorporating clinical and pathologic stage as well as another model excluding patients with missing clinical stage data yielded similar results (data not shown).
Other limitations in our analysis result from weaknesses inherent in any large national database. This includes the inability to discern within the STS-GTD which patients in the thoracoscopy group were converted to thoracotomy intraoperatively. Hence, an intention-to-treat analysis cannot be performed. Our 2 groups to the best of our knowledge represent a cohort that had either VATS or thoracotomy for lobectomy. It is unclear if the 17 patients excluded from the analysis for being listed as both thoracoscopy and thoracotomy represent this group of patients who had intraoperative conversion, as operative notes are not available. If it indeed does, the rate of conversion would be exceedingly low and not consistent with the literature. An additional limitation results that the STS database does not mandate technique and hence variances in VATS techniques such as number and sites of ports, the use of rib spreader, and the extent of mediastinal lymphadenectomy performed cannot be controlled at each participating center. However, no one center contributed disproportionately to the 1281 matched group of patients (Appendix Table 1 ), with no center contributing more than 99 patients to the VATS group or 131 patients to the thoracotomy group. Hence, the results are not skewed by the results of one center exceptionally facile with VATS techniques. A separate analysis examining risks factors for complications after VATS lobectomy will further assess these factors (hospital type and volume) in VATS outcomes.
Furthermore, as complications are self-reported in the STS database, they may be underreported and hence skew our results. As the trend toward VATS lobectomy is a selfdirected effort by surgeons to improve outcomes, an inherent bias may be to minimize complications, facilitate chest tube removal, and hence discharge. Additionally, our analysis also does not include long-term outcomes, as the STS-GTD does not maintain these data. Thus, the long-term effect of the improved postoperative outcomes cannot be determined.
In conclusion, this propensity-matched study of patients in the STS-GTSD found VATS lobectomy to be associated with a lower incidence of multiple postoperative complications compared with lobectomy by thoracotomy, as well as decreased chest tube duration and length of stay. In lieu of a randomized control trial comparing thoracotomy and thoracoscopy for lobectomy, this study provides the best available evidence regarding outcomes after VATs lobectomy. VATs lobectomy may be the preferred strategy for appropriately selected patients with lung cancer.
Discussion
Dr Neil Christie (Pittsburgh, Pa). I have no conflicts to disclose. Earlier studies in thoracoscopic lobectomy focused on feasibility and technique. That having been established, there is now an interest to determine if it is superior to the open thoracotomy technique and, as such, should become the standard of care. This paper has demonstrated a significant decrease in perioperative complications and a shortened length of stay with the thoracoscopic approach to lobectomy.
I would now like to ask a few questions. First, all thoracoscopic lobectomy series have a subset of patients in whom conversion to thoracotomy is required, occasionally due to intraoperative complications such as bleeding. In your analysis, it would seem that these conversion cases are not included in the thoracoscopic group, potentially biasing your study in favor of thoracoscopy. Could you please comment on this?
Dr Subroto Paul (New York, NY). Excellent question. There were patients who were excluded, 17 patients in total, who had VATS lobectomy as well as thoracotomy listed as a procedure performed. Looking at the STS database, it is difficult to ascertain which patients were conversion cases and trying to keep them as an intent-to-treat analysis. So we did exclude those patients, and these are a pure group of patients who just had completed a VATS lobectomy versus an open thoracotomy lobectomy. It does introduce bias and, hence, why this trial is not the equivalent of a randomized trial with an intention-to-treat analysis.
Dr Christie. My second question is, some authors recommend thoracoscopic lobectomy only for stage I node-negative cancers due to the potential of increased difficulty of resection with enlarged lymph nodes. Your study included patients with stage II and stage III cancer. Were you able to do a subset analysis of outcomes with clinical stage II and stage III lung cancers, and would you recommend the thoracoscopic approach as being optimal in these patients?
Dr Paul. A separate analysis was performed using clinical stage as a preoperative variable and including only clinical stage I and stage II patients, and the outcomes were very similar, with the same rates of lower atrial fibrillation, reintubation.
In terms of the second question, could you elaborate a little bit more?
Dr Christie. In that subset of patients who had more advanced disease and clinical nodal disease, do you think the complication rates would still be lower than that seen with thoracotomy?
Dr Paul. It seems from our data that if you had a VATS lobectomy, even for a higher-stage disease, your complication rates are lower, and that is supported by several other single-institution studies. Further analysis of the data would be needed just to look at that subset.
Dr Christie. My final question is, acknowledging the potential selection bias in your study, would you and your colleagues recommend that a prospective randomized study be undertaken of thoracoscopic lobectomy versus open thoracotomy?
Dr Paul. Well, the gold standard would be to have a randomized trial, but the number of patients that would need to be recruited would be in excess of probably 1000 in each arm to show some of these complications, so it would be difficult to perform and conduct. I don't think it will ever be done, but it probably should be done.
Thank you. Dr David Cooke (Sacramento, Calif). Very good presentation, Subroto.
I have a couple questions. One, did you match the thoracoscopic group and the open lobectomy group with patients having mediastinal lymph node sampling or dissections? The assumption is that most of these patients probably did have mediastinal lymph node sampling or dissection, but from previous studies, it's not 100%. In fact, there is a good percentage of patients who do not have sampling or dissection. That might affect possibly the length of chest tube duration, among other outcomes.
Dr Paul. Excellent question. We are kind of limited by the database, which does not include dissection versus sampling within the study, so that is not included as part of the matching process, and that may have affected the results. I think that is one of the questions that we're trying to get at through indirect means through the STS database.
Dr Cooke. The second question is, did you look at differences in terms of intensive care unit admissions and hospital readmissions between the 2 groups?
Dr Paul. That is also another excellent question. Those are parameters that are not included in the STS database, so we could not look at them.
Dr Raja Flores (New York, NY). Nice study, Subroto. I have a word of caution, though. I think when one looks at conversion, it seems as if the ascertainment of the data for the STS database may be a bit skewed with regard to patients who were converted. If you look at the data, you had 17 patients who had both thoracoscopy and thoracotomy out of 1300. Potentially those are conversions. It's not known for sure. If those are conversions, that number is very small. If you look at the prospective study, the CALGB trial, of surgeons who are technically very facile in doing VATS lobectomy, their conversion rate was 14%. So for the database, I think that's low. And whenever you have a group of patients who are converted, the proper analysis is not to exclude them but to include them in the VATS lobectomy group so as to minimize any bias in favor of VATS. Overall, I think it was an excellent study based on the data available, but I think there are some major limitations with the ascertainment of the data for the database that limit the conclusions of this study.
Dr Paul. I agree with your point. There are some things that were limited by the database in terms of what information we can get out of it.
APPENDIX 
